Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | May 12 - 13, 2026

May 14, 2026

•

4 min read

Biotech & Pharma Updates | May 12 - 13, 2026

🧬 BeOne Medicines' Beqalzi (sonrotoclax) receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma as first BCL-2 inhibitor, Novo Nordisk's oral semaglutide delivers up to 21.6% weight loss in Ph3 obesity trial, Vetter breaks ground on new Saarlouis production site, investing €500M ($586.75M) to create up to 2,000 jobs

Christian Cuchapin, +1

Biotech & Pharma Updates | May 11 - 12, 2026

May 13, 2026

•

3 min read

Biotech & Pharma Updates | May 11 - 12, 2026

🧬 Isomorphic Labs raises $2.1B Series B to develop AI drug design engine, accelerate pipeline, FDA Commissioner Marty Makary resigns after turbulent tenure marked by White House tensions, Bristol Myers Squibb, Hengrui Pharma build 13-asset oncology and immune disease pipeline in $15.2B deal

Christian Cuchapin, +1

Biotech & Pharma Updates | May 10 - 11, 2026

May 12, 2026

•

3 min read

Biotech & Pharma Updates | May 10 - 11, 2026

🧬 Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial, Daiichi Sankyo targets $14.6B oncology sales by 2030, aiming for global top-five cancer company status, Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy STEM-PD, equity investment undisclosed

Anis Fahandej-Sadi, +1

Biotech & Pharma Updates | May 7 - 10, 2026

May 11, 2026

•

3 min read

Biotech & Pharma Updates | May 7 - 10, 2026

🧬 Quantinuum plans IPO to fund quantum computing platform for drug discovery, Gilead raises Yeztugo 2026 sales target to $1B after strong launch trajectory, argenx's VYVGART (efgartigimod alfa-fcab) receives FDA label expansion for all adult generalized myasthenia gravis serotypes

Christian Cuchapin, +1

Biotech & Pharma Updates | May 6 - 7, 2026

May 8, 2026

•

3 min read

Biotech & Pharma Updates | May 6 - 7, 2026

🧬 Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B, expanding into U.S. rare neurological drug market, Blackstone invests $250M in Anagram Therapeutics to develop cystic fibrosis EPI therapy, Pierre Fabre, FDA align on Ebvallo BLA resubmission path using updated ALLELE study data

Christian Cuchapin, +1

Biotech & Pharma Updates | May 5 - 6, 2026

May 7, 2026

•

3 min read

Biotech & Pharma Updates | May 5 - 6, 2026

🧬 Eli Lilly pledges additional $4.5B to Indiana campus, expanding genetic medicine and metabolic disease manufacturing, Bayer to acquire Perfuse Therapeutics for up to $2.45B, bolstering eye disease drug pipeline, Novo Nordisk's Wegovy pill hits 1M patients, generates $355M in Q1 sales, beating analyst expectations by 86%

Christian Cuchapin, +1

Biotech & Pharma Updates | May 4 - 5, 2026

May 6, 2026

•

3 min read

Biotech & Pharma Updates | May 4 - 5, 2026

🧬 Pfizer beats Q1 earnings with $14.5B revenue, maintains 2026 guidance despite COVID portfolio decline, Swiss private biotech funding surges 38% to record $1.5B in 2025, marking third straight year of growth, Sanofi invests $294M to expand Toronto AI center, targeting drug discovery and manufacturing acceleration

Christian Cuchapin, +1

Biotech & Pharma Updates | May 3 - 4, 2026

May 5, 2026

•

3 min read

Biotech & Pharma Updates | May 3 - 4, 2026

🧬 Amgen adds $300M to Puerto Rico biologics expansion, bringing total U.S. investment pledges near $2B, Windward Bio raises $165M crossover round, advancing TSLP-targeting immunology antibody programmes, Obesity surpasses oncology as top biopharma pipeline value contributor for first time, per Deloitte analysis

Christian Cuchapin, +1

Biotech & Pharma Updates | April 30 - May 3, 2026

May 4, 2026

•

3 min read

Biotech & Pharma Updates | April 30 - May 3, 2026

🧬 Arvinas' Veppanu (vepdegestrant) receives first-ever FDA approval for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations, UCB to acquire Candid Therapeutics for $2.2B, expanding T-cell engager pipeline for autoimmune diseases, FDA names Katherine Szarama as acting CBER director following Vinay Prasad's departure

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | May 12 - 13, 2026

Biotech & Pharma Updates | May 11 - 12, 2026

Biotech & Pharma Updates | May 10 - 11, 2026

Biotech & Pharma Updates | May 7 - 10, 2026

Biotech & Pharma Updates | May 6 - 7, 2026

Biotech & Pharma Updates | May 5 - 6, 2026

Biotech & Pharma Updates | May 4 - 5, 2026

Biotech & Pharma Updates | May 3 - 4, 2026

Biotech & Pharma Updates | April 30 - May 3, 2026

TLDR Biotech

FAQ

Media Partners